A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

Area of Science:

• Immunology
• Genetics
• Biotechnology

Background:

• Natural killer (NK) cells are crucial for cancer immunotherapy.
• Inhibitory signaling can limit NK cell effectiveness.
• Engineering NK cells can enhance their anti-cancer activity.

Purpose of the Study:

• To develop an efficient CRISPR/Cas9 method for editing human NK cells.
• To enhance NK cell cytotoxicity by knocking out inhibitory genes.
• To establish a platform for generating engineered NK cells for cancer therapy.

Main Methods:

• Utilized CRISPR/Cas9 gene editing in primary human peripheral blood NK cells.
• Efficiently knocked out inhibitory genes ADAM17 and PDCD1.
• Demonstrated gene knockin capability using recombinant adeno-associated virus serotype 6 (rAAV6).

Main Results:

• Achieved up to 90% editing efficiency in primary NK cells.
• Gene-edited NK cells exhibited significantly improved activity, cytokine production, and cancer cell cytotoxicity.
• Expanded gene-edited NK cells to clinically relevant numbers without activity loss.

Conclusions:

• The developed CRISPR/Cas9 platform enables efficient engineering of primary NK cells.
• Engineered NK cells show enhanced anti-cancer properties.
• This method provides a feasible approach for developing universal NK cell-based cancer immunotherapies.